microRNA as a systemic intervention in the specific breast cancer subtypes with C-MYC impacts; introducing subtype-based appraisal tool.
Breast cancer is indisputably a heterogeneous disease, in which a formidable combination of definitely dis-regulated C-MYC and microRNA (miRNA) profiles along with other factors are responsible to generate a specific type of breast cancer. C-MYC as a master regulator of more than 20,000 genes can modify the expression of genes underlying to perform diverse conflicting functional frameworks. The functional spectra of miRNA in the new areas of the evolution of cell behaviors are identified. Here, we endeavor to summarize some recent advances of miRNA applications that can be recruited as combinatorial targeted therapy for patients with breast cancer. Also, it is important to indicate that some exosomal miRNAs including miR-126, miR-122, miR-92-1, miR-19a, and miR-29c together with circular miRNAs, such as miR-21-5p, miR-96-5p, and miR-125b-5p can provide a promising evaluation route in breast cancer prognosis. Furthermore, miR-342, miR-520 for triple negative and hormone receptor-positive types of breast cancer, respectively in collaboration with two detected distinct cluster of miRNAs for different breast cancer cell lines can be applied for more dedicated miRNA-based individualized targeted therapy. New DNA handling capacity of C-MYC-related oncogenic miRNAs through coordination with exosomal miRNAs and circulatory ones can be a potential appraisal tool in breast cancer management. Given the notion that genomic instability is a hallmark of breast cancer, the different horizons that are provided in this review can be employed for more precise and profound analyses to achieve an evaluation signature for breast cancer subtypes.